Johnson & Johnson quarter earnings

Note: This section contains information in English only.
Source: Dukascopy Bank SA
Johnson & Johnson delivered strong first-quarter results, highlighting the strength of its diversified business model. The company reported total sales of $21.9 billion, a 2.4% increase compared to the same period last year. Net earnings surged to $11 billion, up 238%, driven in part by a one-time gain. Adjusted earnings per share rose 2.2% to $2.77, while free cash flow reached approximately $3.4 billion. In terms of business segments, Innovative Medicine saw 4.2% operational growth, led by strong sales of cancer, immunology, and neuroscience treatments. The MedTech segment grew 4.1% operationally, supported by sales in cardiovascular devices (Abiomed) and surgical tools, though orthopedic products showed some weakness.



Regionally, U.S. sales increased by 5.9%, reflecting solid domestic performance. International sales declined 1.8% but rose 2.1% when adjusting for currency impacts. J&J also made key advancements in innovation this quarter, including progress with TREMFYA in inflammatory bowel disease, RYBREVANT + LAZCLUZE in lung cancer, and its new robotic surgery system OTTAVA. The company also strengthened its neuroscience portfolio by completing the acquisition of Intra-Cellular Therapies. Looking ahead, Johnson & Johnson remains confident in its full-year 2025 guidance. However, the company did not provide GAAP forecasts due to uncertainty around legal matters and acquisition-related costs.
Back to articles

Actual Topics

Wed, 23 Apr 2025 12:14:47 GMT

Philip Morris quarter earnings

Philip Morris International reported strong Q1 2025 results, driven by growth in smoke-free products. Smoke-free products like IQOS and ZYN made up 42% of total revenue, with net revenue up 20% and gross profit up 33%. These products are now available in 95 markets. IQOS continued to gain market share in Japan and Europe, while ZYN nicotine pouches grew 53%

Tue, 15 Apr 2025 09:40:59 GMT

BlackRock, Inc. quarter earnings

In the most recent quarter, the firm reported $84 billion in total net inflows, representing 3% annualized organic asset growth. This was driven by a record first quarter for iShares® ETFs, alongside strong inflows into private markets and active strategies. Revenue increased 12% year-over-year, reflecting the positive impact of market appreciation, organic base fee growth, and fees related to the GIP

Subscribe to "Fundamental Analysis" feed

Subscrever
Para saber mais sobre a plataforma de negociação Dukascopy Bank CFD / Forex, SWFX e outras informações relacionadas com negociação,
por favor entre em contato conosco ou faça um pedido de retorno de chamada.
Para obter mais informações sobre uma potencial cooperação,
ligue-nos ou faça-nos um pedido para ser contactado.
Para saber mais sobre as opções binárias do Dukascopy Bank / Plataforma de negociação Forex, SWFX e outras informações relacionadas com Trading,
ligue-nos ou faça-nos um pedido para ser contactado.
Para saber mais sobre a plataforma de negociação Dukascopy Bank CFD / Forex, SWFX e outras informações relacionadas com negociação,
por favor entre em contato conosco ou faça um pedido de retorno de chamada.
Para saber mais sobre a plataforma de Trading / Trading de Crypto/ CFD / SWFX e outras informações relacionadas à negociação,
ligue-nos ou faça-nos uma pedido para ser contactado.
Para saber mais sobre o programa de Introdutor de Negócios e outras informações relacionadas à negociação,
ligue-nos ou faça-nos uma pedido para ser contactado.
Para obter mais informações sobre uma potencial cooperação,
ligue-nos ou faça-nos um pedido para ser contactado.